Kamada Q1 2026: Revenues Surge, Biosimilars Shine

Kamada starts 2026 with a 3% revenue increase, reaching $42.5 million, surpassing expectations despite a $2.4 million shipment delay. Adjusted EBITDA and net income also match or improve from last year. KEDRAB, GLASSIA, VARIZIG, and CYTOGAM drive growth, with KEDRAB set to exceed $90 million in US sales. Kamadas portfolio expansion in Israel and plasma operations in the US boost confidence in their four-pillar strategy. Cash stands at $73.1 million after a dividend payout, indicating focus on mergers and profitable growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f2553f17871fcf00